Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Department of Blood Transfusion, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Hematol Oncol. 2024 Jan;42(1):e3252. doi: 10.1002/hon.3252.
Sarcopenia is a crucial factor in the physical fitness of elderly individuals. This study investigated the prognostic values of multiple parameters of sarcopenia in association with established prognostic factors in elderly Japanese patients with diffuse large B cell lymphoma (DLBCL). As candidate indicators for sarcopenia, the skeletal muscle index (SMI) (cm /m ), the psoas muscle index, the erector spinae muscle index, the visceral fat index, the subcutaneous fat index, and the visceral to subcutaneous fat area ratio at the third lumbar level were assessed by computed tomography at their initial diagnosis in 102 patients with DLBCL over 75 years old those were diagnosed and treated in our institute from 2007 to 2020. The primary endpoint was overall survival (OS), and the secondary endpoint was progression-free survival (PFS). The median age of patients analyzed was 80 years at diagnosis. The sex-specific cut-offs for the indices adopted two approaches: (i) the historical cut-off values established in the previous study for healthy Japanese individuals (Hamaguchi Y. J Cachexia Sarcopenia Muscle. 2018), and (ii) each sex-specific lowest quartile in our cohort. As the results, SMI evaluated by the historical cut-off and sex-specific lowest quartile was identified as the most influential independent prognostic factor for both OS and PFS among various parameters for sarcopenia. Furthermore, we developed an elderly sarcopenia prognostic index (ESPI). ESPI, which combines SMI evaluated by the historical cut-off and LDH > ULN, demonstrated statistically significant prognostic impacts on OS and PFS. Moreover, compared to the R-IPI, ESPI showed the ability to identify intermediate-risk groups and indicated a trend toward improved predictive accuracy. Our study revealed that SMI is the most appropriate assessment method for evaluating sarcopenia and the critical prognostic factor in OS and PFS of elderly patients with DLBCL.
肌少症是老年人身体健康的重要因素。本研究调查了 102 例 75 岁以上老年日本弥漫性大 B 细胞淋巴瘤(DLBCL)患者初诊时 CT 评估的多种肌少症参数与既定预后因素的相关性,这些患者均于 2007 年至 2020 年在我院诊断和治疗。候选肌少症指标包括骨骼肌指数(SMI)(cm/m )、腰大肌指数、竖脊肌指数、内脏脂肪指数、皮下脂肪指数和第三腰椎水平的内脏脂肪与皮下脂肪面积比。主要终点为总生存期(OS),次要终点为无进展生存期(PFS)。分析患者的中位年龄为诊断时 80 岁。所采用的指标的性别特异性截止值有两种方法:(i)既往研究中针对健康日本个体(Hamaguchi Y. J Cachexia Sarcopenia Muscle. 2018)建立的历史截止值,以及(ii)本队列中每个性别特异性最低四分位数。结果表明,SMI 采用历史截止值和性别特异性最低四分位数评估是各种肌少症参数中对 OS 和 PFS 最有影响的独立预后因素。此外,我们开发了老年肌少症预后指数(ESPI)。ESPI 结合了历史截止值评估的 SMI 和 LDH>ULN,在 OS 和 PFS 方面具有统计学显著的预后影响。此外,与 R-IPI 相比,ESPI 能够识别中危组,并表明预测准确性有所提高。本研究表明,SMI 是评估肌少症的最适宜方法,是老年 DLBCL 患者 OS 和 PFS 的关键预后因素。
J Cachexia Sarcopenia Muscle. 2017-4
J Cachexia Sarcopenia Muscle. 2021-8
Ann Hematol. 2018-11-9
Front Med (Lausanne). 2024-12-18